Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Conventional Therapy for Remission Induction in EGPA
NCT02807103Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2016
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by Assistance publique - Hôpitaux de Paris. Started Dec 2016; status: completed.
02
Drugs
rituximab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on NCT02807103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02807103.